Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca’s John Rex joins UK biotech F2G

Takes up the role of chief medical officer at the UK company

F2G John RexJohn Rex has moved from AstraZeneca to F2G to become the Manchester, UK-based drug discovery firm's chief medical officer.

He was previously a senior vice president at AZ, where he served as head of infection within its global medicines development unit, and he has been a non-executive director at F2G since 2012.

Ian Nicholson, chief executive officer at F2G, said: “John's guidance and insight have been instrumental in shaping F2G's development and regulatory strategy. We are delighted that he is now able to increase his commitment to the company as we progress our new class of antifungal agents into our next clinical trials.”  

In his new role Rex will be tasked with helping move F2G's first-in-class antifungal F901218 through phase II clinical trials.

John Rex said: “I am delighted to have the opportunity to work more closely with F2G as we take the first orotomide antifungal forward through phase II and phase III. Just as with antibacterial resistance, antifungal resistance is a growing threat and F2G's discovery of an entirely novel class of IV/PO antifungal agent is a key part of the global response to this challenge.”

Prior to joining AstraZeneca in 2003, Rex was professor of medicine at the University of Texas Medical School and has previously served as the industry representative on the US FDA Anti-Infective Drug Advisory Committee.

5th December 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashley Communications

Ashley Communications is a bespoke, independent medical communications consultancy consistently providing a unique director-delivered client service tailored to individual client...

Latest intelligence

Precision medicine and the changing role of the healthcare professional
The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of...
How will Sustainability and Transformation Plans (STPs) change the NHS commissioning landscape?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, take a look at new commissioning structures and what they mean for pharma...
eyeforpharma Barcelona 2017 highlights: Industry at the brink of transformation
Hear what Anthill's delegates reported back from the biggest eyeforpharma Barcelona yet....

Infographics